AQST vs VTRS
AQST: Aquestive Therapeutics develops advanced, non-invasive pharmaceutical delivery technologies and products, with a primary focus on its oral epinephrine prodrug candidates for severe allergic reactions. VTRS: Viatris is a global healthcare company providing a broad range of high-quality, affordable medicines across both developed and emerging markets.
Side-by-side fundamentals
| Metric | AQST | VTRS | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $4.08 | $18.45 | |
| Market cap | $512M | $21.2B | |
| Net margin FY2025, SEC XBRL | -188.1% | -24.6% | VTRS higher |
| Gross margin FY2025, SEC XBRL | n/a | +35.1% | |
| Operating margin FY2025, SEC XBRL | -159.5% | -18.6% | VTRS higher |
| ROE | n/a | n/a | |
| ROA FY2025, SEC XBRL | -52.2% | -9.5% | VTRS higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.94 | |
| Revenue growth (YoY) FY2025, SEC XBRL | -22.6% | -3.0% | VTRS higher |
| Revenue CAGR (3y) SEC XBRL | -2.2% | -4.2% | AQST higher |
| Dividend yield as of 2026-09-02 | n/a | +2.8% | |
| Dividend streak (yrs) SEC XBRL | 0 | 5 | VTRS higher |
| Beta as of 2026-09-03 | 1.22 | 0.74 | |
| 1-year return as of 2026-10-21 close | -42.0% | +77.6% | VTRS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.